University of Veterinary Medicine Vienna - Research portal

Diagrammed Link to Homepage University of Veterinary Medicine, Vienna

Selected Publication:

Type of publication: Journal Article
Type of document: Full Paper

Year: 2006

Authors: Wolfesberger, B; Hoelzl, C; Walter, I; Reider, GA; Fertl, G; Thalhammer, JG; Skalicky, M; Egerbacher, M

Title: In vitro effects of meloxicam with or without doxorubicin on canine osteosarcoma cells.

Source: J Vet Pharmacol Ther. 2006; 29(1):15-23

Authors Vetmeduni Vienna:

Egerbacher Monika
Skalicky Monika
Thalhammer Johann
Walter Ingrid
Wolfesberger Birgitt

Vetmed Research Units
University Clinic for Small Animals, Clinical Unit of Internal Medicine Small Animals
Institute of Morphology
Institute of Physiology, Pathohysiology and Biophysics, Unit of Physiology and Biophysics
Institute of Physiology, Pathohysiology and Biophysics, Unit of Physiology, Pathophysiology, and Experimental Endocrinology

Cyclooxygenase (COX) inhibitors, already widely used to reduce fever, inflammation and pain, are under increasing consideration as potential agents for the prevention and treatment of neoplasia. As COX-2 was detected in human and canine osteosarcomas, we have evaluated the effect of the preferential COX-2 inhibitor meloxicam on an established D-17 canine osteosarcoma cell line, which expressed, as well as COX-1 and COX-2 also COX-3 (as demonstrated by Western blot). An XTT proliferation kit was used to assess surviving cells after drug treatment. At low concentrations (1, 2, 4 and 10 microm) meloxicam caused an increase in cell numbers while a marked anti-proliferative effect was observed at higher concentrations (100, 200 microm) after 3 days and also 3 weeks of incubation. The chemotherapeutic drug doxorubicin showed a cytotoxic effect at all concentrations (60-1920 nm). Exposure of tumour cells to combinations of meloxicam and doxorubicin revealed synergistic effects (with 240 nm doxorubicin), as well as sub-additive and antagonistic results, especially if combined with concentrations of meloxicam typically found in serum. Care should be taken in concluding, on the basis of one in vitro study, that meloxicam does not have a role in the treatment of canine osteosarcomas given that the results from in vivo studies may differ.

Keywords Pubmed: Animals
Antibiotics, Antineoplastic/therapeutic use*
Bone Neoplasms/drug therapy*
Cyclooxygenase Inhibitors/therapeutic use*
Dose-Response Relationship, Drug
Doxorubicin/therapeutic use*
Drug Synergism
Osteosarcoma/drug therapy*
Thiazines/therapeutic use*
Thiazoles/therapeutic use*
Tumor Cells, Cultured

© University of Veterinary Medicine ViennaHelp and DownloadsAccessibility statement